Page last updated: 2024-11-13

1-butyl-N-[(4-chlorophenyl)methyl]-4-hydroxy-2-oxo-3-quinolinecarboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're describing a molecule with a long and rather complex chemical name! Let's break it down and understand its importance:

**1-butyl-N-[(4-chlorophenyl)methyl]-4-hydroxy-2-oxo-3-quinolinecarboxamide**

This name tells us about the structure of the molecule:

* **Quinolinecarboxamide:** The core structure is a quinoline ring, a nitrogen-containing aromatic ring system, with a carboxamide group attached to it.
* **4-hydroxy:** A hydroxyl group (OH) is attached to the 4th position on the quinoline ring.
* **2-oxo:** A ketone group (C=O) is attached to the 2nd position on the quinoline ring.
* **1-butyl:** A butyl group (four carbon chain) is attached to the 1st position on the quinoline ring.
* **N-[(4-chlorophenyl)methyl]:** This part describes a substituent attached to the nitrogen atom of the carboxamide group. It consists of a benzyl group (methylene linked to a benzene ring) with a chlorine atom attached at the 4th position on the benzene ring.

**Why is it important for research?**

The specific molecule you described doesn't have a well-established research history or a common name, so I can't give you details on its specific importance. However, molecules with similar structures are often investigated for their potential pharmacological activity. Here's why:

* **Quinoline derivatives:** Quinoline-based compounds have a rich history in medicinal chemistry. They have shown activity in various therapeutic areas, including:
* **Antimicrobial activity:** Some quinoline derivatives have antibacterial, antifungal, and antiparasitic properties.
* **Anti-inflammatory activity:** These compounds can inhibit inflammation and have potential for treating inflammatory diseases.
* **Anticancer activity:** Some quinolines have shown promise as potential cancer chemotherapeutic agents.
* **Anti-malarial activity:** Quinine, a natural quinoline alkaloid, has been a mainstay in malaria treatment for centuries.
* **Carboxamide group:** The carboxamide group often contributes to a compound's ability to bind to biological targets, which is essential for drug action.
* **Substituents:** The presence of specific substituents like the hydroxyl group and the chloro-substituted benzyl group can influence the molecule's properties, potentially enhancing its activity or altering its target selectivity.

**To find out more about the specific molecule you mentioned:**

* **Chemical databases:** Search for the full chemical name in databases like PubChem or ChemSpider. These databases might provide information on its potential biological activity, synthesis methods, and any relevant research papers.
* **Scientific literature:** Use the full chemical name or a related structure to search in scientific databases like PubMed or Google Scholar. This will help you find research articles that have investigated similar molecules.

Remember, without specific research context, it's difficult to pinpoint the exact significance of this particular molecule. However, its structure points to potential applications in drug discovery and research.

Cross-References

ID SourceID
PubMed CID54679562
CHEMBL ID1460151
CHEBI ID107570

Synonyms (16)

Synonym
OPREA1_489718
OPREA1_862988
MLS001202795
1-butyl-4-hydroxy-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid 4-chloro-benzylamide
smr000513679
CHEBI:107570
AKOS000622404
HMS2818F06
CHEMBL1460151
1-butyl-n-[(4-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamide
1-butyl-n-[(4-chlorophenyl)methyl]-4-hydroxy-2-oxo-3-quinolinecarboxamide
Q27185895
sr-01000588911
SR-01000588911-1
1-bu-4-ho-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid 4-chloro-benzylamide
BRD-K13162652-001-09-0
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency44.66840.631035.7641100.0000AID504339
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686978
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency3.98110.707912.194339.8107AID720542
PINK1Homo sapiens (human)Potency44.66842.818418.895944.6684AID624263
67.9K proteinVaccinia virusPotency2.23870.00018.4406100.0000AID720579
ParkinHomo sapiens (human)Potency44.66840.819914.830644.6684AID624263
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency15.84890.707936.904389.1251AID504333
P53Homo sapiens (human)Potency70.79460.07319.685831.6228AID504706
chromobox protein homolog 1Homo sapiens (human)Potency56.23410.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency16.46870.004611.374133.4983AID624296; AID624297
Guanine nucleotide-binding protein GHomo sapiens (human)Potency44.66841.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]